ENCell Co., Ltd.
↗Seoul, South Korea
ENCell Co., Ltd. is a South Korean biopharmaceutical company founded in 2018 as a spin-off from the Samsung Medical Center. The company operates as a specialized Contract Development and Manufacturing Organization (CDMO) for cell and gene therapies, while simultaneously maintaining its own internal R&D pipeline for advanced stem cell therapeutics targeting rare and intractable muscle diseases.
ENCell leverages its proprietary 'ENCT' (ENCell Technology) platform, designed to enhance the yield and potency of allogeneic mesenchymal stem cells. The company operates multiple GMP-certified facilities and provides comprehensive services including contract quality testing, process development, and manufacturing for various modalities such as CAR-T, NK cells, exosomes, and viral vectors (AAV, Lentivirus).
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$10M-$25M
Founded:2018
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Total Raised:$8.04M
STOCK
Exchange:KOSDAQ
Market Cap:$0.11B
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 1b/2a
Modalities:Cell therapy, Gene therapy, Exosomes
Active Trials:5
Trial Phases:Phase 1: 5
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Novartis (Cell Processing Center for CAR-T), Janssen (Central Cell Processing Center for CAR-T), Cell Therapies Pty Ltd (APAC CDMO collaboration)
COMPETITION
Position:Emerging
Competitors:Alnylam, Spark Therapeutics, Sana Biotechnology
LEADERSHIP
Key Executives:
Jong-Wook Chang - CEO
LINKS
Website:encellinc.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of ENCell Co., Ltd. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with ENCell Co., Ltd.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.